Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonoprazan–amoxicillin dual therapy vs susceptibility-based tailored therapy as rescue treatment for Helicobacter pylori
ChiCTR2100054440Phase 4Recruiting
- Sponsor
- Army Specialty Medical Center
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of vonoprazan in Helicobacter pylori infection (2 arms), sponsored by Army Specialty Medical Center. Primary endpoint: Eradication rate of Helicobacter pylori. Started Jan 2022; status: recruiting.
02
Drugs
vonoprazan
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on ChiCTR2100054440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100054440.